Table 1:

Participant characteristics

		PET Imaging		CSF
		Mean (SD) / n (%) (N=38)		Mean (SD) / n (%) (N=104)
Age (years)		73.8 (5.3)		74.57 (5.20)
Sex
Men		18 (47.4)		59 (56.7)
Women		20 (52.6)		45 (43.3)
Race
African-American		3 (7.9)		11 (10.6)
Caucasian		35 (92.1)		92 (88.5)
Asian		0 (0.0)		0 (0.0)
More than one		0 (0.0)		1 (1.0)
CDR
0		29 (76.3)		83 (79.8)
0.5		9 (23.7)		21 (20.2)
ApoE4
Negative		25 (65.8)		58 (55.8)
Positive		13 (34.2)		45 (43.3)
Sleep Medications
Yes		4 (10.5)		12 (11.5)
No		34 (89.5)		92 (88.5)
Apnea-Hypopnea Index* (AHI, respiratory events/hour)	Negative (AHI<5)	20 (52.6)		38 (36.5)
	Mild (AHI 5–15)	13 (34.2)		43 (41.4)
	Moderate (AHI 15–30)	5 (13.2)		18 (17.3)
	Severe (AHI>30)	0 (0)		5 (4.8)
Periodic Leg Movement Index (PLMI, leg movements/hour)	Negative (PLMI<15)	21 (55.3)		49 (47.1)
	Low (PLMI 15–45)	7 (18.4)		33 (31.7)
	High (PLMI>45)	10 (26.3)		22 (21.2)
AV-45 PET SUVR		1.44 (0.61)		-----------
AV-1451 PET SUVR		1.40 (0.49)		-----------
Aβ42 (pg/ml)		----------		1012.59 (367.94)
t-tau (pg/ml)		----------		245.46 (119.69)
p-tau (pg/ml)		----------		23.66 (13.46)
AD Pathology	Amyloid neg / Tau neg	20 (52.6)		31 (29.8)
	Amyloid pos / Tau neg	9 (23.7)		35 (33.7)
	Amyloid pos / Tau pos	8 (21.1)		27 (25.9)
	Amyloid neg / Tau pos	1 (2.6)		11 (10.6)
Time Interval from Scan/LP to Sleep Study (years)		AV-45 PET	0.29 (0.48)	1.00 (2.60)
		AV-1451 PET	0.29 (0.40)

^*For the participants who underwent PET imaging (N=38), 4/38 participants used continuous positive airway pressure therapy during sleep monitoring. For participants with CSF (N=104), 12/104 participants used continuous positive airway pressure therapy and 1 participant used lateral position therapy device during sleep monitoring.

SD: standard deviation; CDR: clinical dementia rating; PET: positron emission tomography; CSF: cerebrospinal fluid; SUVR: standardized uptake value ratio; Aβ: amyloid-β; ApoE4: apolipoprotein E4; AD: Alzheimer’s disease; LP: lumbar puncture